Figure 1.
Patient cohort treated with targeted T-cell therapies (n = 28). (A) Swimmer plot representing the PFS of patients treated with TCE or CAR T targeting BCMA (grey box) or other non-BCMA antigens (black box). The red line indicates ongoing response and the blue line indicates progression. The dark green box indicates patients who did not have antigen loss and the light green box indicates patients who had target antigen loss at relapse. The dark red box indicates patients who received TCE and the yellow box indicates patients who received anti-BCMA CAR T. (B) PFS of the patient population in months. (C) The OS of the patient population in months. (D) Box plot comparing the PFS of patients with or without antigen loss at relapse. (E) Circos plot of patient MM-11 based on WGS data. The outer track runs clockwise from chromosome 1 to Y. The inner track shows copy number variations (gains in blue, losses in pink). Lines inside the circle represent SVs (deletions in red, duplications in green, inversions in blue, interchromosomal translocations in black). The copy number and SV plot represents a gain of TNFRSF17. (F) Circos plot of patient MM-19 based on WGS data. The copy number and SV plot represents the gain of POU2AF1. (G) A box plot of TNFRSF17 transcript expression in samples with wild type (WT) vs those with a SV from the CoMMpass data set. (H) A box plot of POU2AF1 transcript expression in samples with WT vs those with an SV from the CoMMpass data set. (I) Dot plot representing the correlation between POU2AF1 and TNFRSF17 expression from the CoMMpass data set. (J) Dot plot depicting the sBCMA (ng/mL) levels measured by sBCMA enzyme-linked immunosorbent assay from patient serum (n = 11 samples). The black horizontal line represents the median.

Patient cohort treated with targeted T-cell therapies (n = 28). (A) Swimmer plot representing the PFS of patients treated with TCE or CAR T targeting BCMA (grey box) or other non-BCMA antigens (black box). The red line indicates ongoing response and the blue line indicates progression. The dark green box indicates patients who did not have antigen loss and the light green box indicates patients who had target antigen loss at relapse. The dark red box indicates patients who received TCE and the yellow box indicates patients who received anti-BCMA CAR T. (B) PFS of the patient population in months. (C) The OS of the patient population in months. (D) Box plot comparing the PFS of patients with or without antigen loss at relapse. (E) Circos plot of patient MM-11 based on WGS data. The outer track runs clockwise from chromosome 1 to Y. The inner track shows copy number variations (gains in blue, losses in pink). Lines inside the circle represent SVs (deletions in red, duplications in green, inversions in blue, interchromosomal translocations in black). The copy number and SV plot represents a gain of TNFRSF17. (F) Circos plot of patient MM-19 based on WGS data. The copy number and SV plot represents the gain of POU2AF1. (G) A box plot of TNFRSF17 transcript expression in samples with wild type (WT) vs those with a SV from the CoMMpass data set. (H) A box plot of POU2AF1 transcript expression in samples with WT vs those with an SV from the CoMMpass data set. (I) Dot plot representing the correlation between POU2AF1 and TNFRSF17 expression from the CoMMpass data set. (J) Dot plot depicting the sBCMA (ng/mL) levels measured by sBCMA enzyme-linked immunosorbent assay from patient serum (n = 11 samples). The black horizontal line represents the median.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal